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Summary. The anticataleptic effects of non-competitive and competitive NMDA 
antagonists as well as those of an agonist at the allosteric glycine binding site of 
the NMDA receptor were tested in the catalepsy model. Some of these drugs 
were further tested in a reaction time task demanding rapid locomotor initiation. 
The results how that the non-competitive NMDA antagonists dizocilpine and 
memantine as well as the competitive antagonists CGP 39551, CGP 37849 and 
CPPene antagonized opamine D2 receptor mediated catalepsy induced by 
haloperidol. D-cycloserine, a partial glycine agonist per se had no effects, but it 
enhanced the anticataleptic effects of dizocilpine when coadministered. Howev- 
er, the effects of CGP 37849 were abolished. Dopamine D1 receptor mediated 
catalepsy induced by SCH 23390 was antagonized by dizocilpine, memantine, 
CPPene, but not by CGP 37849. In the reaction time task dizocilpine, 
memantine and CGP 37849 were tested for their anti-akinetic and 
anti-bradykinetic potencies. All these compounds improved haloperidol- 
induced slowing of reaction time. However, they acted differentially on 
haloperidol-induced slowing of movement execution and decreased initial accel- 
eration. Thus, antagonists at the NMDA receptor may have a therapeutic 
potential in the treatment of Parkinson's disease. Their potency can be manipu- 
lated specifically at the glycine binding site. 
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Introduction 
Glutamate is considered to be the main transmitter mediating synaptic excita- 
tion in the mammalian brain. There exist at least three receptor subtypes for 
glutamate, one of which is the N-methyl-D-aspartate (NMDA) receptor. The 
NMDA receptor can be manipulated pharmacologically with drugs acting 
directly and competitively with respect to NMDA, at the NMDA binding 
site (NMDA as an agonist and AP-5, CGP 37849 and CGP 35991 as competitive 
antagonists). The NMDA binding site gates a cation channel which can be 
blocked by drugs - when in its open state - non-competitively with respect o 
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NMDA (dizocilpine [MK-801], memantine). Additionally a strychnine-insensi- 
tive glycine binding site exists that facilitates the excitation mediated by the 
NMDA binding site (D-cycloserine acts as an agonist at the glycine binding site) 
(Johnson and Ascher, 1987; Hood et al., 1989; Watson et al., 1990). 
With respect o the behavioural pharmacology of NMDA antagonists, it 
has been found that competitive (Morris et al., 1986) as well as non-competitive 
NMDA antagonists (Danysz and Wroblewski, 1989) induce impairments in 
place learning of rats. In the radial 8-arm-maze dizocilpine specifically impaired 
working memory while reference memory remained intact (Schmidt and 
Bischoff, 1988). With local injections and lesion techniques it has been shown 
that disruption of glutamatergic transmission i the hippocampus (Morris et al., 
1986; H61scher and Schmidt, 1991) is critically involved in this form of learning. 
Besides their effects on learning, NMDA antagonists induce a characteristic 
psychomotor stimulation syndrome, e.g. continuous locomotion and sniffing 
(Carlsson and Carlsson, 1990; Tiedtke et al., 1990). The non-competitive ant- 
agonists are much more effective in this regard. Local injections of AP-5 
(Schmidt, 1986), dizocilpine (Imperato, 1991) or NMDA (Schmidt and Bury, 
1988) into the striatum of rats reveal this structure to mediate locomotion and 
sniffing. Interestingly AP-5 infusion into the striatum does not affect learning 
(Hauber and Schmidt, 1989). 
It is well known that, within the striatum, dopamine (DA) agonists also 
induce behavioural activation. Thus, it has been concluded that a population of 
striatal output neurons (probably medium sized GABAergic spiny neurons) 
may exist onto which dopamine and glutamate via the NMDA receptor exert 
opposite ffects (Schmidt et al., 1990). 
Blockade of central dopaminergic neurotransmission by dopamine receptor 
antagonists produces elective motor impairments in rats. These impairments 
seem to be predominantly due to the animals inability to initiate motor be- 
haviour (Skjoldager and Fowler, 1988). This hypothesis i based on findings of 
neuroleptic-treated animals howing akinesia nd rigidity (catalepsy), prolonged 
reaction times (RT) and further motor impairments in various other behavioural 
paradigms (e.g. Amalric and Koob, 1987; Skjoldager and Fowler, 1988). Since 
these motor impairments reflect in part symptoms of Parkinson's disease 
(akinesia, rigidity, tremor), neuroleptic-induced akinesia and rigidity is consid- 
ered to be an animal model of this disease. 
In the present study it was investigated whether or not antagonists at the 
NMDA receptor are able to compensate the behavioural effects of a reduced 
dopaminergic activity. Furthermore, the modulation of these effects by a glycine 
agonist were investigated. 
The behavioural effects were examined in two different models. First, we used 
the catalepsy test where a state of postural immobility, i.e. akinesia, rigidity, was 
induced by administration of haloperidol and possible anticataleptic effects of 
concurrent modulation of the NMDA receptor could be detected. 
Some of the NMDA antagonists found to be effective in the catalepsy test, 
were further investigated in a newly developed reaction time (RT) task for rats, 
which demands rapid initiation of locomotion in order to get a food reward 
(Hauber, 1990). Administration of haloperidol has been found to produce selec- 
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tive impairments oflocomotor initiation in this task: RT was significantly slowed 
and the initial acceleration of the movement was decreased as measured by the 
rate of force development (FS). Furthermore, the movement time (MT) was 
prolonged (Hauber and Schmidt, 1990). This pattern of impairments i  reminis- 
cent to akinesia and bradykinesia in patients with Parkinson's disease. Ac- 
cording to the distinction of Hallett (1990) akinesia refers to delayed movement 
initiation and is characterized by a prolongation of RT. Bradykinesia refers to 
slowness of ongoing movement and is characterized by a prolongation of MT 
and a decrease of the dynamic indices of a movement (Stelmach and 
Worringham, 1988; Wierzbicka et al., 1991). 
The RT task used here is sensitive to possible beneficial effects of compounds 
on movement initiation deficits following administration of haloperidol, since 
anti-akinetic ( hange of RT) and anti-bradykinetic (change of MT and FS) of a 
compound could be detected. 
Materials and methods 
Subjects 
Subjects were male Sprague Dawley rats (Interfauna, F. R. G.) caged in groups with free 
access to water. They were provided with 12 g/d/rat rodent laboratory chow (Altromin, F. 
R. G.) after the daily experimental sessions. The colony room was temperature-regulated 
(22 _+ 3°C) and rats were maintained on a 12-12 h light dark cycle (lights on at 06.00 h). 
Drugs 
Haloperidol 0anssen, F. R. G.), SCH 23390 (Biotrend, F. R. G.), memantine HC1 (Merz, F. 
R. G.), CGP 39551 (Ciba-Geigy, Switzerland), dizocilpine (MK-801) (Merck, Sharpe & 
Dohme, F. R. G.) and D-CPP-ene (SDZ EAA-494) (Sandoz, Switzerland) were dissolved in 
saline and injected at a maximum volume of 0.5 ml. CGP 37849 (Ciba-Geigy, Switzerland) 
was dissolved in saline and the pH was adjusted with 0.1 N NaOH on 7-7.5. D-Cycloserine 
(Fluka, F. R. G.) was dissolved in carbonate buffer and adjusted to pH 8.1-8.5. All drugs 
were given intraperitoneally. 
In the catalepsy test the following drug dosing regimen was used: Dopamine D2 recep- 
tor mediated catalepsy was induced by administration of haloperidol (0.5 mg/kg) and 
the anticataleptic effects of dizocilpine (0.04, 0.16 mg/kg), memantine (5, 10 mg/kg), 
D-cycloserine (12 mg/kg), CGP 37849 (2, 4 mg/kg), CGP 39551 (5, 10 mg/kg) and CPPene 
(5 mg/kg) were tested. The effects of combined administration f D-cyloserine (12 mg/kg) 
with either dizocilpine (0.08 mg/kg) or CGP 37849 (4 mg/kg) were also investigated. 
Dopamine D1 mediated catalepsy was induced by administration f SCH 23390 (1 mg/kg) 
and the anticataleptic effects of dizocilpine (0.16 mg/kg), memantine (10 mg/kg), CGP 37849 
(4 mg/kg) and CPPene (5 mg/kg) were examined. The details of the timing of the injections are 
given in the results ection. 
In the reaction time task haloperidol (0.15 and 0.3 mg/kg), memantine (10 mg/kg) and 
CGP 37849 (4 mg/kg) were given alone, and haloperidol (0.15, 0.3 mg/kg) in combination 
with memantine (10 mg/kg) or CGP 37849 (4 mg/kg). 
Behavioural procedure 
Catalepsy 
Catalepsy was assessed by measuring the time span from placement ofa rat onto a vertical 
grid until the rat removes one of its paws (descent latency), at the most for 180 s (Scheel- 
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Kriiger 1983). The data are presented as means + SEM. They were submitted to a one way 
ANOVA followed by Tukey's protected T-test. 
Movement initiation 
The exact details of the apparatus, behavioural procedure and data recording are described 
elsewhere (Hauber 1990; Hauber and Schmidt, 1990). Briefly, a modified runway was used 
which consisted of a start box and a runway terminating in a goal box. A trained, gradually 
food deprived rat was placed in the start box with the face to the guillotine door blocking 
the entrance to the runway. After a variable delay, a stimulus signalled the simultaneous 
opening of the front door. In response to the stimulus, a rat initiated from a starting 
position rapid locomotion and moved through the runway to the goal box to receive a food 
reward in a food cup (45 mg pellet, Noyes, U.S.A.). Approximately 30 s later, the rat was 
replaced from the goal box into the start box for a new trial. The transition from stance to 
locomotion was recorded by means of a photoelectronic switch situated in front of the start 
box and a force platform mounted below the start box. 
The following measures were taken from each trial: correct reaction time (RT) defined 
as latency (valid range: 100-1000 ms) between stimulus presentation and photobeam inter- 
ruption, correct movement time (MT) (valid range 100-1500 ms) defined as latency between 
photobeam interruption and leaving of the platform and the rate of force development (force 
slope, FS) of the accelerative force. The time resolution of the device was less than 10 ms. 
The trained rats were tested in two daily sessions which consisted of 10 successive trials 
per animal, respectively. The following experimental design was used: stable baseline perfor- 
mance was established in 10 preexperimental raining sessions. Thereafter, the experiment 
was performed on consecutive days with two successive sessions per day, respectively. The 
baseline performance ofthe animals was assessed in the first daily sessions where the animals 
received saline (1 ml/kg i.p.). In the second daily session one drug/saline or drug/drug 
combination of a fixed dose was tested in the same animals. Two different groups of naive 
rats were used to test CGP 37849 (4 mg/kg i.p.) and memantine (10 mg/kg i.p.) alone and in 
combination with haloperidol, respectively. 
The results are based on the means of the parameters in correct rials (+ SEM) per session 
and calculated as follows: The drug effects following single administration were measured 
by comparison of group differences between drug session and corresponding saline session 
from the same animals at the same day and presented as relative change in percent (+ SEM) 
of each parameter. The drug effects on haloperidol-induced deficits of the parameters 
used, were measured by comparisons between sessions with coadministration (haloperidol 
+ drug) and the corresponding haloperidol session (haloperidol given alone at a fixed dose). 
The drug effect was expressed as relative change in percent (+ SEM) of the haloperidol effect. 
Statistical significance of the raw data was calculated by a one-way ANOVA followed by 
the Tukey's protected T-test. The parameters ofthe baseline sessions (saline administration) 
of all days were analyzed by a one-way analysis of variance (ANOVA) to check for stability 
of baseline performance. The significance l vel was p < 0.05. The data were compared with 
results of an earlier study (Hauber and Schmldt, 1990) where dizocilpine was investigated in 
the same task using a similar experimental protocol. 
Results 
Catalepsy 
Haloperidol ,  that preferentially blocks D2-dopamine receptors, induced catalep- 
sy which was reduced by the non-competit ive NMDA-antagon is t  dizocilpine 
(0.04 and 0 .16mg/kg i.p.). Also the adamantan derivative memantine (5 and 10 
mg/kg i.p.) reduced haloperidol- induced catalepsy (Table 1). 
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Likewise, the competitive NMDA antagonists CGP 37849 (2 and 4 mg/kg 
i.p.), CGP 39551 (5 and 10 mg/kg i.p.) and CPPene (5 mg/kg i.p.) reduced 
catalepsy as well (Table 1). However, the glycine agonist D-cycloserine (12 mg/kg 
i.p.) interacted very differently with non-competitive and competitive NMDA 
antagonists: while the anticataleptic effects of the non-competitive NMDA 
antagonist were even strengthened, those of the competitive antagonist were 
completely abolished (Table 2). 
The Dl-dopamine receptor blocker SCH 23390, at a dose of i mg/kg i.p., 
induced catalepsy to a similar degree as haloperidol (0.5 mg/kg) did. The non- 
competitive NMDA-antagonists dizocilpine (0.16 mg/kg i.p.) and memantine 
(10 mg/kg i.p.) antagonized SCH 23390-induced catalepsy. However, the com- 
petitive antagonists had inconsistent effects: while CGP 37849 did not reduce 
SCH 23390-induced catalepsy, CPPene exerted a pronounced anticataleptic 
effect (Table 3). 
Movement initiation 
The baseline performance of both groups of animals remained nearly constant 
on all parameters over all days (p > 0.05 for each parameter, ANOVA, data not 
shown). In addition, comparison of two saline sessions performed on the same 
day showed little variability of the parameters ( ee Fig. 1). Thus, a possible 
influence of days or session on drug-induced effects could be neglected. 
Haloperidol, given alone, caused ose dependently a slowing of RT (akinesia) 
and a profound bradykinesia s indicated by a reduced initial acceleration 
(decrease of FS) and prolonged MT (Fig. 1). Memantine caused a slight and 
significant slowing of RT and impaired initial movement execution powerfully. 
The impairments of MT and FS were about the same degree than those in- 
duced by haloperidol, but were most possibly due to the muscle relaxant prop- 
erties of memantine. CGP 37849 did not alter RT and MT, but reduced 
initial acceleration. By contrast, dizocilpine (data from Hauber and Schmidt, 
1990) induced marked stimulatory effects on movement execution, but left RT 
unchanged. 
The anti-akinetic effects of these compounds, examined by coadministration 
with haloperidol, showed that memantine, CGP 37849 and dizocilpine antago- 
nized the haloperidol-induced slowing of RT (Fig. 2 and 3), respectively. At 
both doses of haloperidol the rank order of potency was the same with 
dizocilpine as the most effective compound followed by CGP 37849 and 
memantine. 
With regard to the reversal of haloperidol-induced bradykinesia, i.e. decrease 
of FS and increase of MT, marked differences between these drugs were found 
(Fig. 2 and 3). Memantine did not antagonize bradykinetic effects, the prolonga- 
tion of MT was even worsened at the lower dose of haloperidol and not improved 
at the higher dose of haloperidol. The decrease of FS was not altered at both 
doses. CGP 37849 improved the haloperidol-induced MT deficit, but did not 
increase deficient FS at both doses, respectively. Dizocilpine antagonized the 
MT prolongation markedly and, above all, increased initial acceleration at both 
doses. 
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Fig. 1. Effects of single administration (i.p.) of saline (SAL: 1 ml/kg), dizocilpine (DIZO: 0.08 
mg/kg), CGP 37849 (CGP: 4 mg/kg) memantine (MEMA: 10 mg/kg) and haloperidol 
(H0.15:0.15 mg/kg; H0.3:0.3 mg/kg) on reaction time (top), movement time (middle) and 
force slope (bottom). The drug effects were measured for each parameter (n= 68-100) by 
comparison ofmean group differences between drug session and according saline session of 
the same animals (N = 8-10) at the same day and presented as relative change in percent 
(±SEM) (*p<0.05, **p<0.01, ANOVA followed by Tukey's protected T-test). 
(Dizocilpine data are from Hauber and Schmidt, 1990) 
Thus, dizocilpine, memantine and CGP 39849 had pronounced anti-akinetic 
effects on haloperidol-induced slowing of RT. With respect o haloperidol- 
induced bradykinesia, only dizocilpine reversed impairments of MT and FS. 
CGP 37849 improved selectively prolonged MT, but left the deficient initial 
acceleration unchanged. Memantine had no anti-bradykinetic effects, but had 
muscle relaxant properties which caused most probably impairments of move- 
ment initiation which are also prominent when coadministered together with 
haloperidol. 
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Fig. 2. Effects of dizocilpine (DIZO: 0.08 mg/kg), CGP 37849 (CGP: 4 mg/kg) or memantine 
(MEMA: 10 mg/kg) administration (i.p.) on haloperidol-induced deficits (0.15 mg/kg) of 
reaction time (top), movement time (middle) and force slope (bottom). The drug effects on 
haloperidol-induced d ficits of the parameters were measured by comparison ofmean group 
differences between sessions with coadministration (haloperidol 0.15 mg/kg + drug) and the 
according haloperidol session (haloperidol 0.15 mg/kg). (N = 8-10, n = 29-97 for each 
parameter and session). The drug effect was expressed as relative change in percent (__+ SEM) 
of the haloperidol effect (*p < 0.05, **p < 0.01, ANOVA followed by Tukey's protected 
T-test). (Dizocilpine data are from Hauber and Schmidt, 1990) 
Discussion 
The main findings of the present study are, that the non-competitive NMDA 
antagonists dizocilpine and memantine as well as the competitive antagonists 
CGP 37849, CGP 39551 and CPPene antagonized D2 mediated catalepsy 
induced by haloperidol. In addition, an enhancement of the anticataleptic effect 
of dizocilpine by D-cycloserine, but not of CGP 37849 by D-cycloserine, was 
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Fig. 3. Effects of dizocilpine (DIZO: 0.08 mg/kg), CGP 37849 (CGP: 4 mg/kg) or memantine 
(MEMA: 10 mg/kg) administration (i.p.) on haloperidol-induced deficits (0.3 mg/kg) of 
reaction time (top), movement time (middle) and force slope (bottom). The drug effects on 
haloperidol-induced d ficits of the parameters were measured by comparison ofmean group 
differences between sessions with coadministration (haloperidol 0.3 mg/kg + drug) and the 
according haloperidol session (haloperidol 0.3 mg/kg). (N = 8-10, n = 73-100 for each 
parameter and session). The drug effect was expressed as relative change in percent (+ SEM) 
of the haloperidol effect (*p < 0.05, **p < 0.01, ANOVA followed by Tukey's protected 
T-test). (Dizocilpine data are from Hauber and Schmidt, 1990) 
found in this test. D1 mediated catalepsy induced by SCH 23390 was antago- 
nized by dizocilpine, memantine, CPPene, but not by CGP 37849. Besides this 
static task, dizocilpine, memantine and CGP 37849 were tested in a dynamic 
task to assess their anti-akinetic and anti-bradykinetic potencies. It was found 
that all these compounds improved haloperidol-induced slowing of reaction 
time. However, slowing of movement execution and decreased initial accelera- 
tion was differentially reversed. 
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There is now general agreement, hat dizocilpine has stimulant effects, e.g. 
it enhances locomotion and sniffing (Clineschmidt et al., 1982; Tiedtke et al., 
1990). Also direct infusion of dizocilpine into the striatum causes these effects 
(Imperato et al., 1990). Further, dizocilpine antagonizes haloperidol-induced 
catalepsy (Schmidt and Bubser, 1989; Elliot et al., 1990) and had the most pro- 
nounced anti-akinetic and anti-bradykinetic properties of the substances tested 
in the RT task. The present findings corroborate the previous studies and 
additionally show an antagonism of dizocilpine against SCH 23390-induced 
catalepsy. 
The studies of Imperato et al. (1991a) show that dizocilpine enhances 
dopamine release and turnover within the striatum and the nucleus accumbens. 
Thus it may be argued that enhanced locomotion and its anticataleptic effects 
are due to this indirect effect of dizocilpine and not primarily by its interac- 
tion with the NMDA receptors. However, several findings argue against his 
view: I. In saline treated rats the dopamine metabolism (DOPAC/DA ratio) in 
nucleus accumbens correlates with locomotor activity. But in dizocilpine treated 
rats, locomotion is not correlated with DOPAC/DA ratio in the accumbens 
(Keseberg et al., 1991). II. in mice depleted of dopamine by reserpine and 
~-methyl-paratyrosine, dizocilpine still produces locomotor stimulation 
(Carlsson and Carlsson, 1990). 
In the striatum, glutamate via the NMDA receptor seems to exert depressant 
effects on behaviour. This view is supported by the finding that NMDA, when 
injected directly into the striatum reduces locomotion, sniffing, rearing and 
feeding (Schmidt and Bury, 1988). Given systemically, it enhances haloperidol- 
induced catalepsy (Mehta and Ticku, 1990) but does not change dopamine 
release (Imperato et al., 1990a). Dopamine release in the striatum and in the 
nucleus accumbens seems to be controlled by non-NMDA receptors (Imperato 
et al., 1990b) in vivo. 
The present data are not entirely consistent with data obtained form in vitro 
models. However, as discussed by Liljequist et al. (1991), a comparison isdifficult 
since in vivo many additional regulatory mechanisms participate in transmitter 
release and uptake. 
Memantine, which is an adamantan derivative with spasmolytic and anti- 
parkinsonian actions, antagonized haloperidol- and SCH 23390-induced cata- 
lepsy. The dopamine-mimetic effect of memantine is not pronounced enough to 
account for its anticataleptic effect. Thus, the recently described non-competitive 
blockade of the NMDA receptor (Bormann et al., 1989; Kornhuber et al., 
1989) may explain its efficacy in the catalepsy model as well as the anti-akinetic 
effects in the RT task. The spasmolytic properties of memantine are most 
probably the reason for the lacking effects on movement execution in the RT 
task. 
Also the competitive NMDA antagonists antagonized haloperidol-induced 
catalepsy (Table 1). However, this is not the case for SCH 23390-induced catalep- 
sy: While CPPene antagonized SCH 23390-induced catalepsy, CGP 37849 
was completely ineffective (Table 3). At present, we have no explanation for this. 
In addition CGP 37849 was found to have pronounced anti-akinetic effects, but 
had, in comparison to dizocilpine, less marked anti-bradykinetic effects. 
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Stimulation of the glycine binding site enhanced the anticataleptic effects of 
dizocilpine (Table 3). This is in accordance with electrophysiological and recep- 
tor-binding studies showing an increase in binding of channel blockers - such 
as dizocilpine - when the glycine binding site is stimulated (Wong et al., 1987). 
However, CGP 37849, which per se has anticataleptic potency, loses its potency 
when combined with D-cycloserine (Table 3). Although this effect cannot be 
explained, it is tempting to speculate, along with some evidence from the litera- 
ture (Monaghan et al., 1988) that stimulation of the glycine binding site converts 
the competitive NMDA binding site in its agonist preferring conformation, thus 
preventing the binding of the competitive antagonists. 
In conclusion, the present study shows that NMDA antagonists exert an- 
ticataleptic effects in the rat and thus may have a therapeutic potential in the 
treatment of Parkinson's disease. This study also shows in which way the various 
binding sites of the NMDA receptor contribute to the expression of behaviour. 
This may help in the search for drugs with minimal side effects but with the 
desired specificity against Parkinson's disease. 
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